StockData
Oruka Therapeutics, Inc. logo

Oruka Therapeutics, Inc. (ORKA) stock

ORKANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 7/30
$96.32−2.92 (-2.94%)

Close on Nov 17, 2026Market cap $6.38BP/E –Yield –

Oruka Therapeutics r&d expenses

Research and development expenses are spending on new products and technology.

Oruka Therapeutics's R&D Expenses for the twelve months ending Jun 30, 2026 was $129.03M. For fiscal 2025 it was $100.64M, up 9834.8% from the year before. Over ten years it grew 33.4% a year on average. The highest annual figure on record is $100.64M in fiscal 2025.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$100.64M+9834.8%
FY2023Dec 31, 2023$1.01M-78.7%
FY2022Dec 31, 2022$4.75M-65.7%
FY2021Dec 31, 2021$13.83M+177.1%
FY2020Dec 31, 2020$4.99M+172.3%
FY2019Dec 31, 2019$1.83M-56.8%
FY2018Dec 31, 2018$4.24M-69.9%
FY2017Dec 31, 2017$14.08M+14.0%
FY2016Dec 31, 2016$12.35M+74.8%
FY2015Dec 31, 2015$7.06M+25.6%
FY2014Dec 31, 2014$5.63M+92.1%
FY2013Dec 31, 2013$2.93M+168.1%
FY2012Dec 31, 2012$1.09M-52.8%
FY2011Dec 31, 2011$2.32M-25.5%
FY2010Dec 31, 2010$3.11M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$43.26M+79.6%
Q1 FY2026Mar 31, 2026$29.15M+46.3%
Q4 FY2025Dec 31, 2025$27.64M+7.6%
Q3 FY2025Sep 30, 2025$28.99M+55.2%
Q2 FY2025Jun 30, 2025$24.09M+14498.2%
Q1 FY2025Mar 31, 2025$19.93M+42293.6%
Q3 FY2024Sep 30, 2024$25.69M+7878.6%
Q2 FY2024Jun 30, 2024$18.67M+7251.6%
Q1 FY2024Mar 31, 2024$165.00K-57.7%
Q4 FY2023Dec 31, 2023$47.00K-23.0%
Q3 FY2023Sep 30, 2023$322.00K-68.6%
Q2 FY2023Jun 30, 2023$254.00K-82.9%
Q1 FY2023Mar 31, 2023$390.00K-82.1%
Q4 FY2022Dec 31, 2022$61.00K-98.5%
Q3 FY2022Sep 30, 2022$1.02M-70.2%
Q2 FY2022Jun 30, 2022$1.49M-58.5%
Q1 FY2022Mar 31, 2022$2.18M-24.2%
Q4 FY2021Dec 31, 2021$3.94M+23.0%
Q3 FY2021Sep 30, 2021$3.44M+841.9%
Q2 FY2021Jun 30, 2021$3.58M+831.5%
Q1 FY2021Mar 31, 2021$2.88M+728.8%
Q4 FY2020Dec 31, 2020$3.20M+628.2%
Q1 FY2020Mar 31, 2020$365.00K-44.9%
Q4 FY2019Dec 31, 2019$384.00K-38.6%
Q3 FY2019Sep 30, 2019$347.00K-53.1%
Q2 FY2019Jun 30, 2019$440.00K-61.9%
Q1 FY2019Mar 31, 2019$662.00K-61.5%
Q4 FY2018Dec 31, 2018$625.00K-77.9%
Q3 FY2018Sep 30, 2018$740.00K-78.8%
Q2 FY2018Jun 30, 2018$1.15M-74.4%
Q1 FY2018Mar 31, 2018$1.72M-47.0%
Q4 FY2017Dec 31, 2017$2.83M-9.2%
Q3 FY2017Sep 30, 2017$3.49M-6.2%
Q2 FY2017Jun 30, 2017$4.51M+54.8%
Q1 FY2017Mar 31, 2017$3.25M–
Q4 FY2016Dec 31, 2016$3.12M–
Q3 FY2016Sep 30, 2016$3.72M–
Q2 FY2016Jun 30, 2016$2.91M–

More Oruka Therapeutics figures

See a number that looks wrong?